Clinical trials: Colorectal Carcinoma (CRC)
Colorectal Cancer, Colorectal Adenoma
The Implementation of Genetic Risk for Colorectal Cancer Screening
The goal of this study is to investigate genetic risk for colorectal cancer utilizing polygenic risk scores (PRS) for adults over 45 who have not received their first colonoscopy. The main questions it hopes to address are: 1.
- Conditions
- Colorectal Cancer, Colorectal Adenoma, Colorectal Polyp
- Trial name
- PRO-GENE-COLON (NCT07621757)
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Endeavor Health
Colorectal Cancer
Longitudinal Study of Symptoms in Colorectal Cancer
The goal of this research study is to learn more about the pain and/or other symptoms that patients may experience within five years from CRC diagnosis.
- Trial name
- NCT00777192
- Testing
- Questionnaires
- Where
- United States
- Volunteers
- 509 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00086931
- Testing
- capecitabine, oxaliplatin, conventional surgery
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer, Colorectal Cancer
AI-Assisted Chemotherapy Side Effect Management
This two-stage adaptive randomized controlled trial evaluates the feasibility and preliminary efficacy of large language model (LLM)-assisted intervention for managing chemotherapy side effects in patients with solid tumors.
- Trial name
- ALLIANCE (NCT07198581)
- Testing
- LLM-assisted chemotherapy side effect management
- Where
- South Korea
- Volunteers
- 174 people
- Sponsor
- Incheon St.Mary's Hospital
Metastatic Colorectal Cancer
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Background: Each year, more than 32,000 people in the United States are diagnosed with colorectal cancer that has returned or progressed after treatment and spread to other organs.
- Trial name
- NCT06149481
- Testing
- Retifanlimab, Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform, N-803
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have recurrent or…
- Trial name
- NCT00022477
- Testing
- BMS-247550
- Where
- 15 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Chicago
Preventive Health Services
Coordinated Endoscopic Colorectal Cancer Screening
The investigators aim to use a randomized design to test the effects of 1) tailored physician recommendations, relative to non-specific recommendations, and 2) coordinated physician office management systems on patient adherence…
- Trial name
- NCT00327457
- Testing
- Help with physician office and patient management, Tailored physician recommendation letter
- Where
- United States
- Volunteers
- 599 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Colorectal Cancer
Aspirin and/or Folic Acid in Preventing Recurrent Colorectal Polyps
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of aspirin and/or folic acid may be effective in preventing recurrent polyps in patients who have…
- Trial name
- NCT00033319
- Testing
- folic acid, acetylsalicylic acid
- Where
- 32 sites in United Kingdom
- Sponsor
- Queen's Medical Center
Colorectal Cancer Screening
Systems of Support (SOS) to Increase Colon Cancer Screening and Follow-up Supplement
Ancillary Aim #1 We will evaluate intervention effects by comparing binary outcomes for screening (yes/no) in the primary SOS study.
- Trial name
- NCT01052922
- Testing
- 3 sample g-SENSA, 2 sample InSure, 1 sample OC-Micron
- Where
- United States
- Volunteers
- 2,260 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
KRAS G12D Mutation, Advanced Solid Cancer
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation.
- Trial name
- NCT07023731
- Testing
- ARV-806
- Where
- 14 sites in United States
- Volunteers
- 76 people
- Sponsor
- Arvinas Inc.
Ovarian Neoplasms, Endometrial Neoplasms
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors.
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06400472
- Testing
- Sofe-M, bevacizumab, carboplatin
- Where
- 25 sites in United States, Australia and 5 more
- Volunteers
- 575 people
- Sponsor
- Eli Lilly and Company
Resectable Hepatic Metastases of Colorectal Cancer
Study of Immune Response and Liver Damage Induced by Chemotherapy for Liver Metastases of Colorectal Cancer
The immune response at primary tumor has a major role in the prognosis of colorectal cancer (CRC). Some studies suggest a prognosis value of cytotoxic T cell and memory T cells at primary tumor greater than tumoral stage.
- Trial name
- METAHEP (NCT01673607)
- Testing
- Biopsie liver
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Poitiers University Hospital
Colorectal Cancer
Implementation of the ERAS in Colorectal Cancer Patients: a Single Arm Study
The goal of this study is to implement and investigate the efficacy of an Early Recovery After Surgery (ERAS) protocol in South Korean colorectal cancer patients.
- Trial name
- NCT06729736
- Testing
- ERAS protocol
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Seoul National University Hospital
Colorectal Carcinoma, Lung Adenocarcinoma
Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer
This early phase I trial studies the direct effects on cancer cells of the drugs binimetinib and palbociclib, in patients with KRAS-positive lung, colorectal, or pancreatic cancer that can be removed by surgery (operable).
- Conditions
- Colorectal Carcinoma, Lung Adenocarcinoma, Malignant Solid Neoplasm, Pancreatic Carcinoma
- Trial name
- NCT04870034
- Testing
- Binimetinib, Palbociclib, Therapeutic Conventional Surgery
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
This phase I trial investigates the side effects and best dose of talazoparib when given together with trifluridine/tipiracil for the treatment of patients with colorectal or gastroesophageal cancer that has spread to nearby…
- Conditions
- Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT04511039
- Testing
- Trifluridine and Tipiracil Hydrochloride, Talazoparib Tosylate
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Roswell Park Cancer Institute
Recurrent Colon Cancer, Recurrent Rectal Cancer
SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer
This randomized phase II trial is studying how well SB-715992 works in treating patients with advanced or metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer
- Trial name
- NCT00103311
- Testing
- ispinesib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Factors Related to Adverse Events in Colorectal Cancer
Coordinated multi-center project with several complementary goals in each one of the sub-projects included. Objectives: 1.To determine risk factors of death, or major complications in the short term; 2.To determine risk factors…
- Trial name
- CARESS-CCR (NCT02488161)
- Testing
- No intervention
- Volunteers
- 2,600 people
- Sponsor
- Hospital Galdakao-Usansolo
Colorectal Neoplasms
Dendritic Cell Vaccination in Patients With Advanced Colorectal Cancer
Dendritic cells loaded with tumor antigens induce cytotoxic T-cells which have been proved capable of killing both melanoma and breast cancer cells. Melanoma and colorectal cancer cells express some common antigens.
- Trial name
- NCT00311272
- Testing
- MelCancerVac
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Colorectal Cancer Metastatic
Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma
The optimal duration of systemic treatment in patients with advanced colorectal cancer is unknown. In this study the effects of bevacizumab and low-dose continuous chemotherapy with capecitabine is investigated in patients who…
- Trial name
- CAIRO3 (NCT00442637)
- Testing
- capecitabine + bevacizumab, observation
- Where
- Netherlands
- Volunteers
- 635 people
- Sponsor
- Dutch Colorectal Cancer Group
Advanced Cancer, Angiosarcoma
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1…
- Conditions
- Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer
- Trial name
- NCT03860272
- Testing
- Botensilimab, Balstilimab
- Where
- 18 sites in United States, United Kingdom
- Volunteers
- 499 people
- Sponsor
- Agenus Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.